| 3.87 -0.07 (-1.78%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.13 | 1-year : | 6 |
| Resists | First : | 4.4 | Second : | 5.13 |
| Pivot price | 3.62  |
|||
| Supports | First : | 3.44 | Second : | 2.84 |
| MAs | MA(5) : | 3.78 |
MA(20) : | 3.63 |
| MA(100) : | 3.53  |
MA(250) : | 6.62 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.1 |
D(3) : | 70.5 |
| RSI | RSI(14): 62 |
|||
| 52-week | High : | 29.45 | Low : | 2.84 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ QLGN ] has closed below upper band by 5.9%. Bollinger Bands are 32.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.12 - 4.14 | 4.14 - 4.16 |
| Low: | 3.7 - 3.73 | 3.73 - 3.75 |
| Close: | 3.83 - 3.87 | 3.87 - 3.9 |
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Thu, 01 May 2025
Nasdaq Threatens to Delist Qualigen on May 5: Company Plans Last-Minute Appeal - Stock Titan
Thu, 01 May 2025
Qualigen Therapeutics, Inc. Receives Notification of - GlobeNewswire
Tue, 01 Apr 2025
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme - GlobeNewswire
Tue, 01 Apr 2025
Qualigen Therapeutics Delays Yearly Financial Report - TipRanks
Tue, 01 Apr 2025
Qualigen Therapeutics to acquire Marizyme in strategic move - Investing.com
Thu, 05 Dec 2024
Qualigen Therapeutics Announces Regained Compliance with - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 735990 (%) |
| Held by Institutions | 3.7 (%) |
| Shares Short | 120 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -126.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.31818e+007 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.26364e+007 |
| Qtrly Earnings Growth | 635 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | 1.28 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.03 |
| Dividend | 0 |
| Forward Dividend | 44740 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|